🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the fight against increasingly resistant strains of the infection, according to health experts.

An International Health Concern

The sexually transmitted infection are escalating worldwide, with figures suggesting over 82 million new cases per year. Particularly high rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This approval signifies a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

As per results detailed in a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the existing first-line therapy, which combines two antibiotics. The trial included over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in numerous low-income and middle-income countries.

Doctors treating patients have shared positive views. Having a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for patients and to halt the transmission of untreatable gonorrhoea globally.